ReviewOncogene2005
Deregulated TGF-beta signaling in leukemogenesis.
Review in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03023384 (Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- NUP214 in Acute Myeloid Leukemia.Cells · 2025Review
- Mechanism of THBS1 Regulation of MDCK Cell Proliferation and Apoptosis Through TGF-β/Smad Signalling.International journal of molecular sciences · 2025Article
- SPAG6 regulates cell proliferation and apoptosis via TGF-β/Smad signal pathway in adult B-cell acute lymphoblastic leukemia.International journal of hematology · 2024Article
- Development of a prognostic model for children with neuroblastoma based on necroptosis-related genes.Frontiers in genetics · 2022Article
- Genomic analysis of biomarkers related to the prognosis of acute myeloid leukemia.Oncology letters · 2020Article
- Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from Higher-Risk MDS Patients by Regulating the ROS-Related Wnt/Stem cells international · 2020Article
- ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation.Scientific reports · 2018Article
- Abnormal expression of TGF-beta type II receptor isoforms contributes to acute myeloid leukemia.Oncotarget · 2017Article
- TET1 is a tumor suppressor of hematopoietic malignancy.Nature immunology · 2015Article
- The gene expression patterns of BMPR2, EP300, TGFβ2, and TNFAIP3 in B-Lymphoma cells.Cancer biology & medicine · 2014Article
- TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20.Oncogene · 2013Article
- Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid.PloS one · 2012Article
- Genome-wide screening of indicator genes for assessing the potential carcinogenic risk of Nanjing city drinking water.Ecotoxicology (London, England) · 2011Article
- Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth.The Journal of pharmacology and experimental therapeutics · 2011Article
- Article
- Characterisation of genome-wide PLZF/RARA target genes.PloS one · 2011Article
- Article
- Article
- The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells.The Journal of clinical investigation · 2009Article
- Gfi-1 represses CDKN2B encoding p15INK4B through interaction with Miz-1.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular homeostasis is tightly controlled by the various pathways that regulate cell proliferation and cell death. Breaking this balance is often associated with cancer development. The transforming growth factor-beta (TGF-beta) pathway plays an important role in cellular homeostasis by regulating cell growth inhibition, cellular senescence, differentiation and apoptosis. Deregulated TGF-beta signaling is known to be involved in a variety of human cancers, including those of the colon, pancreas, breast and prostate. While TGF-beta is a potent negative regulator of hematopoiesis, the role of aberrant TGF-beta signaling in leukemogenesis remains largely unknown. Recently, evidence demonstrating deregulated TGF-beta signaling in leukemogenesis, particularly in acute promyelocytic leukemia (APL), has started to emerge. In this review, we summarize the current progress towards the understanding of the molecular mechanisms by which aberrant TGF-beta signaling may participate in leukemogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.